JP2019502384A - 疾患の不均一性を特徴づけるための転移性疾患における、循環腫瘍細胞（ｃｔｃ）の単一細胞ゲノムプロファイリング - Google Patents

疾患の不均一性を特徴づけるための転移性疾患における、循環腫瘍細胞（ｃｔｃ）の単一細胞ゲノムプロファイリング Download PDF

Info

Publication number
JP2019502384A
JP2019502384A JP2018535034A JP2018535034A JP2019502384A JP 2019502384 A JP2019502384 A JP 2019502384A JP 2018535034 A JP2018535034 A JP 2018535034A JP 2018535034 A JP2018535034 A JP 2018535034A JP 2019502384 A JP2019502384 A JP 2019502384A
Authority
JP
Japan
Prior art keywords
ctc
cancer
cells
heterogeneity
nuclear
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018535034A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019502384A5 (https=
Inventor
ディッタモア ライアン
ディッタモア ライアン
マルリヌッチ デナ
マルリヌッチ デナ
Original Assignee
エピック サイエンシス， インコーポレイテッド
エピック サイエンシス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エピック サイエンシス， インコーポレイテッド, エピック サイエンシス， インコーポレイテッド filed Critical エピック サイエンシス， インコーポレイテッド
Publication of JP2019502384A publication Critical patent/JP2019502384A/ja
Publication of JP2019502384A5 publication Critical patent/JP2019502384A5/ja
Priority to JP2021054561A priority Critical patent/JP2021118689A/ja
Priority to JP2023086666A priority patent/JP2023116530A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N15/1429—Signal processing
    • G01N15/1433—Signal processing using image recognition
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/16—Assays for determining copy number or wherein the copy number is of special importance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N2015/1006—Investigating individual particles for cytology

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Dispersion Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Signal Processing (AREA)
  • Physiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
JP2018535034A 2016-01-06 2017-01-05 疾患の不均一性を特徴づけるための転移性疾患における、循環腫瘍細胞（ｃｔｃ）の単一細胞ゲノムプロファイリング Pending JP2019502384A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021054561A JP2021118689A (ja) 2016-01-06 2021-03-29 疾患の不均一性を特徴づけるための転移性疾患における、循環腫瘍細胞（ｃｔｃ）の単一細胞ゲノムプロファイリング
JP2023086666A JP2023116530A (ja) 2016-01-06 2023-05-26 疾患の不均一性を特徴づけるための転移性疾患における、循環腫瘍細胞（ｃｔｃ）の単一細胞ゲノムプロファイリング

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662275659P 2016-01-06 2016-01-06
US62/275,659 2016-01-06
US201662344703P 2016-06-02 2016-06-02
US62/344,703 2016-06-02
PCT/US2017/012317 WO2017120324A1 (en) 2016-01-06 2017-01-05 Single cell genomic profiling of circulating tumor cells (ctcs) in metastatic disease to characterize disease heterogeneity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021054561A Division JP2021118689A (ja) 2016-01-06 2021-03-29 疾患の不均一性を特徴づけるための転移性疾患における、循環腫瘍細胞（ｃｔｃ）の単一細胞ゲノムプロファイリング

Publications (2)

Publication Number Publication Date
JP2019502384A true JP2019502384A (ja) 2019-01-31
JP2019502384A5 JP2019502384A5 (https=) 2020-02-06

Family

ID=59273946

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018535034A Pending JP2019502384A (ja) 2016-01-06 2017-01-05 疾患の不均一性を特徴づけるための転移性疾患における、循環腫瘍細胞（ｃｔｃ）の単一細胞ゲノムプロファイリング
JP2021054561A Pending JP2021118689A (ja) 2016-01-06 2021-03-29 疾患の不均一性を特徴づけるための転移性疾患における、循環腫瘍細胞（ｃｔｃ）の単一細胞ゲノムプロファイリング
JP2023086666A Pending JP2023116530A (ja) 2016-01-06 2023-05-26 疾患の不均一性を特徴づけるための転移性疾患における、循環腫瘍細胞（ｃｔｃ）の単一細胞ゲノムプロファイリング

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021054561A Pending JP2021118689A (ja) 2016-01-06 2021-03-29 疾患の不均一性を特徴づけるための転移性疾患における、循環腫瘍細胞（ｃｔｃ）の単一細胞ゲノムプロファイリング
JP2023086666A Pending JP2023116530A (ja) 2016-01-06 2023-05-26 疾患の不均一性を特徴づけるための転移性疾患における、循環腫瘍細胞（ｃｔｃ）の単一細胞ゲノムプロファイリング

Country Status (8)

Country Link
US (2) US20190025312A1 (https=)
EP (1) EP3400311A4 (https=)
JP (3) JP2019502384A (https=)
CN (2) CN115323054A (https=)
AU (2) AU2017205443A1 (https=)
CA (1) CA3010311A1 (https=)
EA (1) EA201891571A1 (https=)
WO (1) WO2017120324A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022527264A (ja) * 2019-03-26 2022-06-01 テンプス ラブス，インコーポレイティド 病理組織スライド画像からのバイオマーカーの判定方法
JP2023543667A (ja) * 2020-09-04 2023-10-18 コーニンクレッカ フィリップス エヌ ヴェ ２つ以上のゲノム突然変異および／または遺伝子発現関連パラメータの値に基づいて腫瘍の不均一性を推定するための方法および対応する装置
US12165236B2 (en) 2018-05-14 2024-12-10 Tempus Ai, Inc. Predicting total nucleic acid yield and dissection boundaries for histology slides
US12524826B2 (en) 2018-05-14 2026-01-13 Tempus Ai, Inc. Determining biomarkers from histopathology slide images

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3045918B1 (en) 2009-10-21 2017-12-06 The Scripps Research Institute Method of using non-rare cells to detect rare cells
EA201691496A1 (ru) 2014-01-27 2016-12-30 Эпик Сайенсиз, Инк. Диагностика биомаркеров рака предстательной железы с помощью циркулирующих опухолевых клеток
EA201691682A1 (ru) 2014-02-21 2017-02-28 Эпик Сайенсиз, Инк. Способы анализирования редких циркулирующих в крови клеток
US11514289B1 (en) 2016-03-09 2022-11-29 Freenome Holdings, Inc. Generating machine learning models using genetic data
US11222194B2 (en) * 2016-12-30 2022-01-11 Ventana Medical Systems, Inc. Automated system and method for creating and executing a scoring guide to assist in the analysis of tissue specimen
EP3431611A1 (en) 2017-07-21 2019-01-23 Menarini Silicon Biosystems S.p.A. Improved method and kit for the generation of dna libraries for massively parallel sequencing
CN109060989B (zh) * 2018-08-29 2021-07-30 重庆市肿瘤研究所 应用iTRAQ技术研究三阴性乳腺癌外泌体差异表达蛋白的方法
CN109658981B (zh) * 2018-12-10 2022-10-04 海南大学 一种单细胞测序的数据分类方法
KR102343947B1 (ko) * 2019-09-30 2021-12-27 주식회사 피디젠 환자 정보 분석을 이용한 암 재발 및 전이 모니터링 시스템을 이용한 비즈니스모델
CN112164420B (zh) * 2020-09-07 2021-07-20 厦门艾德生物医药科技股份有限公司 一种基因组瘢痕模型的建立方法
WO2022225995A1 (en) * 2021-04-19 2022-10-27 F. Hoffmann-La Roche Ag Methods and systems for gene alteration prediction from pathology slide images
EP4445141A1 (en) * 2021-12-07 2024-10-16 Epic Sciences, Inc. Enhanced characterization of breast cancer
JP2025505920A (ja) * 2021-12-21 2025-03-05 ファウンデーション・メディシン・インコーポレイテッド ゲノムプロファイリングの成功を予測するための方法及びシステム

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014050404A (ja) * 2005-09-20 2014-03-20 Veridex Llc ユニーク配列のｄｎａプローブを作製するための方法および組成物、ｄｎａプローブの標識、ならびにこれらプローブの使用
WO2014165785A2 (en) * 2013-04-05 2014-10-09 Myriad Genetics, Inc. Methods and materials for assessing homologous recombination deficiency
WO2015048740A1 (en) * 2013-09-30 2015-04-02 The Scripps Research Institute Genotypic and phenotypic analysis of circulating tumor cells to monitor tumor evolution in prostate cancer patients
US20150212089A1 (en) * 2014-01-30 2015-07-30 Epic Sciences, Inc. Circulating tumor cell diagnostics for biomarkers predictive of resistance to androgen receptor (ar) targeted therapies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2937051A1 (en) * 2014-01-17 2015-07-23 Ontario Institute For Cancer Research (Oicr) Biopsy-driven genomic signature for prostate cancer prognosis
WO2015112999A1 (en) * 2014-01-27 2015-07-30 Epic Sciences, Inc. Detection of prostate specific membrane antigen (psma) expression on circulating tumor cells (ctc)
EA201691496A1 (ru) * 2014-01-27 2016-12-30 Эпик Сайенсиз, Инк. Диагностика биомаркеров рака предстательной железы с помощью циркулирующих опухолевых клеток

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014050404A (ja) * 2005-09-20 2014-03-20 Veridex Llc ユニーク配列のｄｎａプローブを作製するための方法および組成物、ｄｎａプローブの標識、ならびにこれらプローブの使用
WO2014165785A2 (en) * 2013-04-05 2014-10-09 Myriad Genetics, Inc. Methods and materials for assessing homologous recombination deficiency
WO2015048740A1 (en) * 2013-09-30 2015-04-02 The Scripps Research Institute Genotypic and phenotypic analysis of circulating tumor cells to monitor tumor evolution in prostate cancer patients
US20150212089A1 (en) * 2014-01-30 2015-07-30 Epic Sciences, Inc. Circulating tumor cell diagnostics for biomarkers predictive of resistance to androgen receptor (ar) targeted therapies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANALYTICAL CHEMISTRY, vol. vol.86, no.22, p.11013-11017, JPN6020036716, 2014, ISSN: 0004355425 *
BREAST CANCER RESEARCH, vol. vol.16:211, JPN6020036714, 2014, ISSN: 0004514880 *
J. CIRC. BIOMARK., vol. vol.4:3, doi:10.5772/60725, JPN6020036712, 2015, ISSN: 0004514879 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12165236B2 (en) 2018-05-14 2024-12-10 Tempus Ai, Inc. Predicting total nucleic acid yield and dissection boundaries for histology slides
US12524826B2 (en) 2018-05-14 2026-01-13 Tempus Ai, Inc. Determining biomarkers from histopathology slide images
JP2022527264A (ja) * 2019-03-26 2022-06-01 テンプス ラブス，インコーポレイティド 病理組織スライド画像からのバイオマーカーの判定方法
JP7548932B2 (ja) 2019-03-26 2024-09-10 テンプス エーアイ，インコーポレイティド 病理組織スライド画像からのバイオマーカーの判定方法
JP2023543667A (ja) * 2020-09-04 2023-10-18 コーニンクレッカ フィリップス エヌ ヴェ ２つ以上のゲノム突然変異および／または遺伝子発現関連パラメータの値に基づいて腫瘍の不均一性を推定するための方法および対応する装置

Also Published As

Publication number Publication date
JP2023116530A (ja) 2023-08-22
AU2017205443A1 (en) 2018-07-19
CN108884494A (zh) 2018-11-23
AU2023202282A1 (en) 2023-05-11
JP2021118689A (ja) 2021-08-12
EP3400311A4 (en) 2019-07-03
CA3010311A1 (en) 2017-07-13
US20220390451A1 (en) 2022-12-08
WO2017120324A1 (en) 2017-07-13
EP3400311A1 (en) 2018-11-14
CN115323054A (zh) 2022-11-11
EA201891571A1 (ru) 2019-01-31
US20190025312A1 (en) 2019-01-24

Similar Documents

Publication Publication Date Title
US20220390451A1 (en) Single cell genomic profiling of circulating tumor cells (ctcs) in metastatic disease to characterize disease heterogeneity
US20250155440A1 (en) Methods of determining therapies based on single cell characterization of circulating tumor cells (ctcs) in metastatic disease
US20230033449A1 (en) Circulating tumor cell diagnostics for detection of neuroendocrine prostate cancer (nepc)
US20250180564A1 (en) Single cell genomic profiling of circulating tumor cells (ctcs) in metastatic disease to characterize disease heterogeneity
US20200333345A1 (en) Circulating tumor cell diagnostics for prostate cancer biomarkers
CN107250796B (zh) 用于鉴别对雄激素受体靶向疗法的抵抗性的循环肿瘤细胞诊断
US20190285636A1 (en) ANDROGEN RECEPTOR VARIANT 7 AS A BIOMARKER FOR TREATMENT SELECTION IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (mCRPC)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191223

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191223

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200925

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200929

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201125

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210601